Medical Review Semaglutide scientific content was reviewed for accuracy on 2026-07-24 By Dr
I mean that seriously because its never been the case that so many people are talking about the impact that they can have on weight loss, diabetes, insulin resistance, and appetite suppression
If a patient with ovarian cancer has obesity or type 2 diabetes, and youre weighing options for metabolic management, GLP-1RAs become even more attractive
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
